focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.
One of the many good things about this share is that you don’t have to wait until Monday for potential news
Previously quite an illiquid share. Someone getting in early as the potential is there. Long way to go for some of us ex STGR holders but welcome nevertheless
BMN is a beast in the making according to Myles. Hope he is right although it does now look as though all the pieces of the jigsaw are finally coming together
The publicity on mass testing all seems to be coming from the UK Gov but is it being given priority in any other countries given that CV is a global phenomenon?
Successful capital raise at 0.275p and 10 hole drilling to start next month. Potential copper deposits also found. Not aware any capital raise was ongoing but at least half a chance now I might get some money back from the old STGR days
https://twitter.com/gjbrandon/status/1303228402820886528?s=20
Interesting comment from one of our partners. All will be revealed later this month. What might he be referring to?
Interesting quote from this ST article:
In Whitehall meetings last week it was agreed that theatres and sports venues will become key beneficiaries of the government’s Operation Moonshot programme which aims to test up to 4 million people a day for the coronavirus using new saliva tests that give results in minutes
If AVCT is at the heart of Operation Moonshot it is no wonder Al says increasing manufacturing capacity is our biggest issue. Exciting times
Further evidence that affimers work and are world class and that has huge significance for the future growth of AVCT’s diagnostic and therapeutic work. Big Pharma will understand this even if trolls and traders don’t
Just had an E mail from Primary to say my new shares will be in my HL account on Thursday as agreed with the broker
Further statistical evidence to support saliva based testing. Definitely worth a read
Whilst most value is likely to be added through a successful LFT antigen test, don’t underestimate the impact on updates on our neutralising therapies, sewage collaboration with SKIN and MWG both of whom had good gains last week and of course BAMS. News on all 3 could well come before any flow test results and should at the very least keep the shorters on their toes.
Great news but it still refers to an anti body test. Any explanations?
Thought he said nigh on impossible but might be wrong
Key question is up to 1 billion dollars was not mentioned in the original RNS so how accurate is the Business Weekly article? Fantastic news if it is accurate
RD, As I am sure you are aware BBN has tweeted a series of posts today all of which highlight the huge potential of AVCT post COVID 19 and specifically the manner in which monies made from the LFDs will speed up the development of the suite of diagnostic and treatment trials waiting to be delivered. AVCT is not a one trick pony as the derampers would want us to believe
My understanding is that any potential manufacturer of the LFD antigen test would have to send off batches to be clinically validated so Medusa saying the branding on the test may differ shouldn’t create a problem.
5.1 interesting saying they are currently experiencing a high volume of demand for the product.
Just trying to get a bit of clarity from the excitement following the updated Medusa web site:
- the test published on this site is clearly an antibody test as confirmed by their late inclusion of the word immunity and to that extent the late flurry of buys in the last 15 minutes was based on a false premise.
- Medusa’s web site makes clear they will not market antigen tests that compete with AVCT and there will be no need for Al to RNS on Monday any clarification as initially suggested.
- Plenty of bad press on Medusa that I do not subscribe to. They didn’t jump the gun as it is not AVCT‘s test and they have some very experienced professionals in their team with a lot more retail experience than the people who are criticising them.
- There is clearly a lot going on behind the scenes re infrastructure, manufacturing partners etc indicating the extent of the global market that is potentially available to AVCT.
- In the meantime the clinical validation process continues, the excitement builds and we are a day nearer to the news w are all hoping to wake up to.
The stand out quote from a CEO who is not known for overstating
As part of the application process you are asked to state your broker and it will be to this account where your allotted shares will be sent
According to a person leading the research into a vaccine quoted in the ST today there is only a 1 in 3 chance of ever finding a vaccine. AVCT will not only have the best diagnostic tests available but also a potential neutralising treatment